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Abstract: Bitter Melon (Momordica charantia) is a widely used traditional remedy for 
hyperglycemia. While the medicinal properties of this plant have been studied extensively 
using in vitro and animal models, the clinical efficacy and safety in humans is largely 
unknown. This review discusses the benefits and limitations of bitter melon 
supplementation in the context of epidemic levels of insulin resistance and pre-diabetes 
throughout the world. 
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1. Introduction 
An estimated 79 million adult Americans have pre-diabetes, a condition that is preventable and 
treatable if recognized early [1]. Patients presenting with pre-diabetes have glycated hemoglobin 
(HgA1c) and blood sugar levels that are below the clinical threshold to be classified as type 2 diabetes 
but are higher than normal (HgA1c 5.7–6.4%; fasting blood glucose 100–125 mg/dL; 2-hour plasma 
glucose with 75 g oral glucose tolerance test between 140–199) [2]. However, the early stages of 
damage to the heart and circulatory system have already begun and without intervention, pre-diabetics 
are at risk for becoming diabetic and developing cardiovascular disease [3,4]. While the percentage of 
pre-diabetes is equal among blacks and whites (35%), a disproportionate percentage of non-Hispanic 
blacks progress to diabetes compared with their non-Hispanic white counterparts (18.7% vs. 10.2%) [1]. 
Guidelines established by the American Association of Clinical Endrocrinologists (AACE) suggest 
that regular glucose monitoring and adoption of healthful lifestyles (diet and exercise) may reverse 
uncomplicated pre-diabetes [5].  
Nearly 40% of Americans use complementary and alternative medicine (CAM) for health 
promotion and the treatment of illness [6]. Among this group, between 2 and 3 million specifically use 
CAM in an attempt to lower blood sugar levels and to treat various stages of diabetes, despite limited 
studies of their safety and efficacy [7]. CAM is most commonly used by immigrant groups and their 
descendants, including Asians, Latin Americans, Africans, Indians, West Indians, and Native Americans 
[7]. However, CAM use is not limited to these groups and many Americans have become increasingly 
aware of CAM practices from their immigrant and Native American neighbors. Because of the rapidly 
changing demographics of the United States and the wide use of CAM, primary care providers need to 
be knowledgeable about CAM in order to appropriately advise their patients regarding the safety and 
efficacy of these practices. For example, potentially harmful interactions with conventional 
medications may occur if an effective CAM therapy is added to conventional therapy [7]. Furthermore, 
some patients, especially among vulnerable populations, may not disclose CAM use to their primary 
care provider because of historic mistrust of the health care system [8]. Many CAM therapies are based 
on traditional remedies and have not been evaluated under rigorous scientific conditions (e.g., large-
scale, placebo-controlled, randomized clinical trials using standardized protocols) [7]. Nonetheless, 
25% of prescription drugs on the market today contain active compounds derived from plants or plant-
derived synthetic analogs (e.g., metformin and the French lilac plant) [9]. Approximately 80% of the 
world’s population routinely depends on plant derived therapies to prevent and treat illness [9]. 
Previous animal studies have observed an increase in insulin secretion and glucose uptake with the 
use of some herbal compounds [10]. However, it remains important to carefully evaluate the potential 
effectiveness and safety of these compounds in controlling blood sugar levels in humans. Evidence of 
the therapeutic benefits of folkloric medications cannot be presumed solely from their historical use or 
data extracted from animal studies alone. Below, we review the clinical evidence to date pertaining to Int. J. Environ. Res. Public Health 2014, 11 2330 
 
Momordica charantia (bitter melon), a traditional herbal remedy used since ancient times by Chinese 
and Ayurvedic practitioners to treat high blood sugar and early signs of diabetes [11,12]. 
2. Description 
Bitter melon is a commonly consumed vegetable that is found throughout the sub-tropical world 
(China, India, Thailand, East Africa, The Caribbean, Central and South America) and is known by 
various names, such as balsam pear, bitter gourd, carilla, cerasee (wild variety), cundeamor, goo-fah, 
and karela [13,14]. The plant has been well studied in animal models and several mechanisms of action 
have been proposed for its anti-diabetic properties (Table 1). At latest count, approximately 228 
different compounds with possible medicinal properties, acting alone or in combination, have been 
isolated from bitter melon fruit, seeds, leaves, stems, pericaps, endosperm, callus tissues, and 
cotyledons [15]. Among these, the most actively studied constituents shown to improve glycemic 
control include charatin, polypeptide-p, vicine, momordin, and similar derivatives (e.g., momordinol, 
momordicilin, momorcharin, momordicin) [15–17]. 
Table 1. Antidiabetic mechanisms of bitter melon (Momordica charantia) in animal models. 
Mode of Action  Model  Observed Effects 
1.  Insulin signaling 
pathway  
  db/db mice 
  Whole fruit powder, lipid, 
saponin or the 
hydrophilic residue of 
bitter melon fruit 
  5 weeks 
  ↓ Hba1c 10% 
  ↓ Protein tyrosine phosphatase 1B (PTP 1B) activity 
by 20% [18]  
  Non- obese diabetic mice
  Recombinant ADMc1 
(active ingredient isolated 
from Bitter Melon) 
  ↓ Glucose after 8 h intraperitoneal injection [19]  
  C57Bl6/J mice, high fat 
diet 
  Bitter melon fruit 
  16 weeks 
  ↑ Liver tyrosine phosphorylation  
  ↑ Insulin receptor substrate 1 
  ↓ Plasma apoB-100 and apoB-48 in HFD-fed mice 
[20] 
  C57Bl6/J mice, high fat 
diet 
  Bitter melon, aquatic 
extract powder 
  12 weeks 
In skeletal muscle: 
  ↑ Insulin receptor substrate-1 (IRS-2) 
  ↑ Insulin receptor β (IRβ)  
  ↑ Phosphatidylinositide 3-kinases (PI 3-K)  
  ↑ Glucose transporter type 4 (GLUT4)  
  ↑ Phosphorylation of insulin receptor substrate-1, 
Akt1 and Akt2 
  ↓ Body weight, plasma glucose, insulin, leptin levels, 
and HOMA-IR [21]  
 Int. J. Environ. Res. Public Health 2014, 11 2331 
 
Table 1. Cont. 
Mode of Action  Model  Observed Effects 
2.  Gluconeogenic & 
Glycolysis enzymes 
  Rats 
  Bitter melon fruits 
extracts 
  ↓ Hexokinase activity and glucose uptake activity in 
intestinal fragments [22]  
  Streptozotocin treated rats
  Bitter melon leaf extract 
  90 min 
  ↓ Activity ~30% Hepatic glucose-6-phosphatase and 
fructose 1,6-bisphosphatase activities [23]  
  C57Bl6/J, high fat diet 
  Bitter melon fruit extract 
  4 weeks 
 
  ↑ mRNA and protein expression of glucose 
transporter 4 (GLUT4) 
  ↓ Hyperglycemia, hyperleptinemia, HbA1c and free 
fatty acid  
  ↑ Adipose PPARγ and liver PPARγ mRNA levels 
[24]  
3.  Pancreatic Beta 
cells  
  Streptozotocin Wistar rats
  Bitter melon fruit pulp 
  28 days 
  ↑ Fasting blood, glucose, serum insulin and cell 
function 
  ↑ Diabetic rat cells were abundant with insulin 
granules 
  ↑ Islet size and total cell area 
  Number of β-cells ↑2 fold with bitter melon treatment 
[25] 
  Alloxan treated albino 
rats 
  Bitter melon fruit 
  15 and 30 days 
  Regeneration of B cells in islets of Langerhans & 
neoformation of islets 
  Treatment protected against hydrophobic 
degeneration in liver 
  ↑ Glycogen localization in liver [26]  
4.  Lipid Regulation    C57bl6/J, high fat diet 
  Bitter melon seed oil 
  5 weeks 
White adipose tissue: 
  ↑ Phosphorylation of acetyl-CoA carboxylase 
  ↑ cAMP-activated protein kinase (PKA) [27] 
  C57BL/6, high fat diet 
  Bitter melon fruit 
  12 weeks 
Epididymal adipose tissues (EAT) and brown adipose 
tissues (BAT) 
  ↓ Mast cell recruitment 
  ↓ Interleukin-6 (IL-6) and tumor necrosis factor-α 
(TNF-α)  
  ↓ Macrophage infiltration 
  ↓ M1/M2 phenotype ratio of macrophages [28]  
  Sprague-Dawley rats, 
high fat diet 
  Bitter melon juice 
  7 weeks 
  ↓ Visceral fat mass, hepatic triacylglycerol 
  ↑ Serum free fatty acids 
  ↑ Peroxisome proliferator-activated receptor 
coactivator-1 α (PGC-1-α ) [29]  
3. Clinical Reports 
The clinical potential of bitter melon has been examined in several human cell line experiments.  
In studies of hepatoblastoma cells (HepG2), it has been shown to be a potent inhibitor of triglyceride 
synthesis and ApoB secretion [30]. Similarly, momordin (a constituent of bitter melon) increases the Int. J. Environ. Res. Public Health 2014, 11 2332 
 
expression of peroxisome proliferator-activated receptor (PPAR)  mRNA in HepG2, which is 
important in the regulation of glucose metabolism and fatty acid storage [31]. Bitter melon juice also has 
been demonstrated to significantly reduce sterol regulatory element-binding protein 1c (SREBP-1c) when 
applied to primary preadipocytes, further highlighting the prospective benefit of this compound in 
glycemic control. However, direct evidence in humans has been limited to mostly anecdotal case 
reports and a few conflicting studies among diabetic or non-diabetic “at-risk” patients (Table 2). 
Accordingly, the effect of bitter melon on blood sugar levels and disease progression in pre-diabetics 
must be extrapolated from these studies. 
Table 2. Summary of clinical studies on bitter melon (Momordica charantia) 
§. 
First Author 
[Ref.] 
(Location) 
Sample  Design  Treatment  Jadad 
Score 
Results 
Ahmad [32] 
(Bangladesh) 
100 Moderate type II 
diabetics 
Case series  
(no referent group)
Aqueous homogenized 
suspension (single treatment), 
Non-standardized dose 
C  ↓Fasting serum 
glucose  
(p < 0.001), 
↓Post-prandial 
serum glucose  
(p < 0.001) 
Akhtar [33] 
(Pakistan) 
8 Uncomplicated, 
maturity-onset 
diabetics 
Case series  
(no referent group)
Powdered bitter melon,  
50 mg/kg body weight twice 
daily for 7 days after breakfast 
and dinner along with milk 
C  ↓Mean blood 
sugar levels  
(p < 0.05) 
Baldwa [34] 
(India) 
5 Healthy 
volunteers, 
5 Diabetic referents, 
9 Pts. with diabetes 
mellitus 
Unblinded,  
Non-randomized, 
Clinical trial 
Subcutaneous (single injection) 
of Polypepide-p, 
Arbitrary dosing  
C  ↓Fasting serum 
glucose  
(p < 0.05) 
Dans [35] 
(Philippines) 
40 Newly physician 
diagnosed or poorly 
controlled type 2 
diabetes 
Double-blind, 
Randomized, 
Placebo-
controlled, 
Intent-to-treat 
2 Capsules of bitter melon thrice 
daily for 3 months,  
Medication prepared by 3rd 
party to conceal allocation 
B  ↓Fasting plasma 
glucose  
(p = 0.5862), 
Achieved study 
power was only 
11% 
Fuangchan 
[36] 
(Thailand) 
143 Newly 
diagnosed type 2 
diabetes 
Double-blind, 
Active-control, 
Pill counting to 
monitor 
compliance ,  
Intent-to-treat 
2 Capsules (500 mg) before and 
after meals for 4 weeks 
A  ↓Mean 
fructosamine 
levels  
(−10.2 µmol/L; 
95%CI = −19.1 
to −1.3) 
Grover [37]  
(India) 
14 NIDDM  
(mixed sex), 
6 IDDM  
(female only) 
Case series (no 
referent group) 
Bitter melon seeds, 
Single treatment 
C  ↓Post-prandial 
serum glucose  
(p = 0.001) Int. J. Environ. Res. Public Health 2014, 11 2333 
 
Table 2. Cont. 
First Author 
[Ref.] 
(Location) 
Sample  Design  Treatment  Jadad 
Score 
Results 
Habib [38] 
(Bangladesh) 
8 NIDDM (3F, 5M) 
taking  
½–1 tablet 
glibenclamide 
randomly selected 
from diabetic center 
Open-label, Cross-
over design (15 day 
wash-out period 
between treatments) 
Powdered, dried fruit  
(4 gm/patient) administered 
consecutively for  
21 days 
C  ↓Post-
prandial 
serum 
glucose  
(p = 0.001) 
John [39] 
(India) 
26 Type 2 diabetics  Unblinded, 
Randomized, Clinical 
trial 
2 Tablets (1 gm) dried fruit 
thrice daily after meals for 4 
weeks 
C  ↓Fasting 
serum 
glucose  
(p > 0.05), 
↓Post-
prandial 
serum 
glucose  
(p > 0.05) 
Kasbia [14] 
(Canada) 
5 Non-diabetic, 
overweight men 
Randomized, 
Blinded,  
Placebo-controlled, 
Cross-over study 
Eligible participants 
underwent 3 experimental 
conditions in a randomized 
order: placebo,  
50 mg/kg,100 mg/kg body 
weight of freeze-dried juice, 
Single treatments separated 
by 1-week washout period, 
Placebo capsules filled with 
inert cellulose 
C  No effect on 
plasma 
glucose 
Khanna [40] 
(India) 
6 Juvenile referents, 
5 Juvenile diabetes, 
2 Maturity onset 
diabetes referents, 
6 Maturity onset 
diabetes 
Unblinded,  
Non-randomized, 
Clinical trial 
Subcutaneous, 
Polypepide-p (single 
treatment), 
Arbitrary dosing depending 
upon severity of diabetes 
C  ↓Serum 
glucose  
(p < 0.05) at 
selected time 
point Int. J. Environ. Res. Public Health 2014, 11 2334 
 
Table 2. Cont. 
First Author 
[Ref.] 
(Location) 
Sample  Design  Treatment  Jadad 
Score 
Results 
Kochhar [41] 
(India) 
60 Non-
insulin-
dependent 
male diabetics 
Case series (no 
referent group) 
Raw powered mixture (bitter 
melon fruit, fenugreek seeds, 
jambu seeds) in the form of 
capsules (Group I) or salty 
biscuits (Group 2), 
Daily supplementation  
of 1 g for 1.5 months followed 
by 2 g for 1.5 months, 
Fresh, immature bitter melon 
fruit procured from a single lot 
grown locally and stored in 
airtight plastic containers until 
use 
C  ↓Fasting glucose  
(p < 0.01), 
↓Postprandial glucose 
(p < 0.01), 
↓Decreased oral 
hypoglycemic drug 
intake (p < 0.05) 
Leatherdale 
[42] 
(England) 
9 NIDDM 
 
Case series (no 
referent group) 
Water-soluble extract of bitter 
melon fruit (single treatment), 
Later received fried bitter 
melon fruit for 8 to 11 weeks 
C  ↓Blood glucose 
concentration during 
50 g oral glucose 
tolerance test  
(p < 0.05) 
Lim [43] 
(Philippines) 
40 Newly 
diagnosed type 
2 diabetes 
mellitus (18 
males, 22 
females) 
Double-blind, 
placebo-
controlled trial, 
Medications 
prepared by a 
third party to 
conceal allocation
Tablets containing dried bitter 
melon leaves, 
Single oral dose (3 treatment 
groups of 60, 80,  
100 mg/kg/day), 
Placebo tablets matched in 
appearance to active 
compound 
B/A 
(published 
in journal 
without 
impact 
factor or 
indexed in 
PubMed) 
↑Insulin levels at  
15 min (p = 0.0402), 
↓Average plasma 
glucose levels at  
15 min (p = 0.0121), 
100 mg/kg/day dose 
of bitter melon was 
more effective than 
lower doses and 
placebo in reducing 
mealtime glycemic 
excursions within 4 
hour postdose, with 
more rapid return to 
baseline levels Int. J. Environ. Res. Public Health 2014, 11 2335 
 
Table 2. Cont. 
First Author 
[Ref.] 
(Location) 
Sample  Design  Treatment  Jadad 
Score 
Results 
Pons [44] 
(Puerto Rico) 
8 Patients  
(7 diabetic,  
1 normal) 
Case series (no 
referent group) 
2 Pills (0.10g of bitter 
melon extract powder) 
taken after each meal, 
Duration of 
administration varied up 
to 3 weeks 
C  ↓Blood sugar in 2 
patients (p > 0.05) 
Purification, 
(unpublished 
report in Duque 
[45]) 
(Phillipines) 
260 Type 2 
diabetics 
Phase III trial, 
Randomized block 
design, 
(bitter melon,  
n = 128; 
glibenclamide,  
n = 132) 
Tablet (100 mg/kg/day) 
for 12 weeks 
C 
(sufficient 
details not 
provided) 
↓Fasting plasma 
glucose (p < 0.05), 
Bitter melon and 
glibenclamide were 
comparable in terms of 
efficacy and safety 
Rosales [46] 
(Philippines) 
27 Type 2 
diabetics with 
suboptimal 
glycemic 
control 
Unblinded,  
Randomized, 
Cross-over, 
Clinical trial 
200mL bitter melon tea 
after meals, 
Placebo consisted of tea 
made from leaves of 
Camellia sinensis, 
24 Week study 
C  ↓HbA1c (63% 
reduction,  
p = 0.005), 
↓Fasting serum 
glucose (p = 0.403) 
Srivastava [47] 
(India) 
7 Mild to 
severe 
diabetics 
Case series (no 
referent group) 
100 mL Aqueous 
extract, 
Separate group given 15 
g dried fruit powder 
thrice a day in equal 
doses of 5 g each, 
3 Week treatment period
C  ↓Post-prandial serum 
glucose for aqueous 
group only (p < 0.01) 
Tongia [48]  
(India) 
15 NIDDM  Unblinded,  
Non-random 
allocation 
200mg Twice daily soft 
bitter melon extract  
(7 days treatment), 
C  ↓Post-prandial serum 
glucose  
(p < 0.001) 
Tsai [49]  
(Taiwan) 
42 Patients 
with metabolic 
syndrome 
(mean age 
45.7; range 23 
to 63 years) 
Open-label, 
Uncontrolled, 
Supplementation 
trial 
4.8 g Lyophilized bitter 
melon powder daily for 
3 months 
C  ↓Metabolic syndrome 
(p = 0.021), 
Improved insulin 
resistance at visit 2 
and return to nearly 
baseline levels after 
stopping bitter melon 
(p > 0.05) Int. J. Environ. Res. Public Health 2014, 11 2336 
 
Table 2. Cont. 
First Author 
[Ref.] 
(Location) 
Sample  Design  Treatment  Jadad Score  Results 
Welhinda [50] 
(Sri Lanka) 
18 Newly 
diagnosed 
maturity onset 
diabetics 
Cross-over design 100 mL Aliquots of clear 
bitter melon juice given 
orally, 
Placebo (same patients) 
received 100 mL distilled 
water, 
Single administration of 
treatment and placebo 
C  ↓ Glucose 
tolerance curves 
compared with 
referent glucose 
tolerance curves  
(p < 0.01) 
Zänker [51]  
(Germany)  
124 Type 2 
diabetes 
mellitus (age > 
40 years) not 
treated with 
insulin but 
receiving  
anti-diabetics 
Prospective, 
placebo-
controlled, 
randomized, 
double-blinded,  
Participants 
required to stop 
taking dietary 
supplements, 
Compliance not 
monitored 
Special water soluble bitter 
melon standardized at 10% 
charantin, 
Daily dose - 1 g  
(2 capsules), 
Second active group 
received chromium and zinc 
supplementation, 
Screening phase + 4-week 
depletion phase + 4-month 
intervention phase, 
No information provided on 
the country of origin for 
bitter melon, part of the 
plant used (e.g., seeds, pulp, 
leaves), or self-life 
B/A 
(published in 
journal 
without 
impact factor 
or indexed in 
PubMed) 
↓ HbA1c,  
p = 0.0002, 
No hypoglycemic 
or other adverse 
events reported 
§  Studies identified through a search of PubMed, Google Scholar, and published manuscript 
reference lists using key words (Momordica charantia, bittermelon, bitter gourd, and karela).   
A ≥ 4, B = 2–3, C ≤ 1; NIDDM = non-insulin dependent diabetes mellitus; IDDM = insulin 
dependent diabetes mellitus. 
Studies illustrating the benefit of bitter melon on lowering blood sugar have appeared sporadically 
in the literature for over 70 years. On the island countries of Puerto Rico, Cuba, and the Dominican 
Republic, bitter melon has been traditionally used to treat high blood sugar and diabetes since the early 
1900s [44]. In a non-randomized administration of bitter melon in the form of a dried powder alcoholic 
extract to eight patients (seven diabetic, one normal) at a clinic in San Juan, Puerto Rico, a positive 
blood sugar lowering effect was observed in two of the patients, one of whom was   
non-diabetic [44]. However, it was emphasized in this report that “the continued and indiscriminate 
use of any such remedy by the public, if ineffective, unavoidably results in detrimental and even fatal 
procrastination of appropriate treatments.”  
In Britain, immigrant herbal practitioners have long claimed that bitter melon (karela) is an 
effective therapy for lowering blood sugar levels [52]. In one of the first case reports to be published in 
a main-stream medical journal, bitter melon reportedly reduced the urine sugar levels of a 40 year-old Int. J. Environ. Res. Public Health 2014, 11 2337 
 
diabetic Pakistani woman, who hitherto had difficulty controlling her diabetes with conventional drug 
(chlorpropamide) therapy and dietary restriction [52]. Furthermore, she was able to effectively reduce 
the dose of chlorpropamide necessary to control her high blood sugar. However, physicians were 
cautioned to be aware of this potential food-drug interaction among their Indian and Pakistani diabetic 
patients who also may be receiving concurrent treatment from an herbal practitioner.  
Polypeptide-p is one of the few active compounds in bitter melon that has been studied in clinical 
trials. The extraction of polypeptide-p (consisting of 166 residues) from the fruit, seeds, and tissue of 
frozen bitter melon was first described at the Third International Congress of Plant Tissue and Cell 
Culture held in Leicester, England during the summer of 1974 [34]. The compound closely resembles 
bovine insulin with the exception of one extra amino acid, methionine [40]. Sometimes referred to as 
“plant insulin”, polypeptide-p tests negative in immunoassays against bovine insulin and reportedly 
does not invoke an antigenic response in humans. Clinical research examining the effect of 
polypeptide-p on blood sugar levels has mainly focused on the subcutaneous administration of this 
compound. By circumventing the neutralizing proteolytic enzymes of the intestines, polypeptide-p is 
believed to have greater activity when injected subcutaneously compared with oral administration [13].  
In a study of nine patients with diabetes mellitus (six juvenile, two asymtomatic, one maturity onset) 
ranging from age 16 to 52 years, subcutaneous injection of polypeptide-p resulted in a statistically 
significant drop in mean blood sugar levels (2-tailed, paired t-test, p = 0.05) [34]. No appreciable 
decrease in blood sugar levels was observed among either normal (n = 5) or diabetic (n = 5) referents 
receiving placebo injections. However, participants were not randomized between bitter melon and 
placebo. Compared with a typical peak effect seen after 2–3 h for regular insulin, polypeptide-p treated 
patients peaked after 4–12 h. A similar hypoglycemic effect was observed in a subsequent   
(non-randomized) study (presented at the 20th Annual Meeting of the American Society of 
Pharmacognosy, Purdue University) in which polypeptide-p was subcutaneously injected into   
11 diabetic patients (five juvenile, six maturity onset) compared with eight diabetic referents (six 
juvenile, two maturity onset) [22]. Those with a history of ketoacidosis, cerebrovascular accidents, 
acute myocardial infarction, and renal failure were excluded from the study.  
Among non-insulin-dependent diabetics, a water-soluble extract from locally obtained fresh (raw) 
bitter melon juice has been observed to significantly reduce mean blood sugar levels and 
correspondingly increase mean insulin levels during a 50 g oral glucose test, compared with standard 
test of distilled water (p < 0.05) [42]. Frozen juice squeezed from bitter melon pulp and seeds from the 
plant manifested equally positive results in studies of diabetics [37,50]. However, a weaker effect upon 
glucose levels was reported following the consumption of either fried fruit or dried powder forms of 
bitter melon [33,42]. A tea prepared from bitter melon leaves reduced HbA1c levels by 63%   
(p = 0.005) compared with a referent tea (Camellia Sinensis) [46]. Anecdotally, some of the patients 
who received bitter melon powder for 7 days claimed to remain well and complication-free without 
any medication for about 1–2 months [33]. In a preliminary open-label uncontrolled supplementation 
trial of 42 participants, 4.8 g of lyophilized wild bitter melon powder significantly decreased the rate of 
metabolic syndrome after three months of supplementation and the improved status remained for one 
month after the supplementation ceased (p = 0.021) [49]. An increase of insulin resistance also was 
noted for visit 2, but did not reach statistical significance. In a small case series of seven patients, an 
aqueous extract of 100 g of chopped bitter melon fruit taken each morning for 3 weeks resulted in a Int. J. Environ. Res. Public Health 2014, 11 2338 
 
54% drop in blood sugar levels (p < 0.01) [47]. The effect was much lower (25% drop) in the   
powder-treated group. Furthermore, drinking an aqueous suspension of bitter melon pulp led to 
decreased levels of both fasting and post-prandial blood sugar (mean reduction of 18%) in a case series 
of 100 moderate non-insulin dependent diabetics [32].   
A statistically significant decrease (p < 0.001) in post-prandial blood sugar level was observed 
among patients administered 4 g of bitter melon fruit powder for 21 days in a cross-over study of 8  
non-insulin dependent diabetic patients (five males, three females already taking ½–1 tablets daily of 
glibenclamide) randomly selected from the diabetic center in Rajshahi, Bangladesh [38]. Patients 
ranged in age from 35 to 60 years. Each was served the same breakfast items before a 5 mL blood 
sample was taken 2 h later. A combination regimen of bitter melon and fenugreek seeds was found to 
have a synergistic effect in lowering blood sugar levels. In a similar study, a powdered mixture of 
bitter melon fruit, jamun seeds, and fenugreek seeks administered to 60 non-insulin-dependent male 
diabetics significantly reduced their fasting and postprandial glucose levels and decreased their dose of 
oral hypoglycemic drugs [41]. 
Only a few randomized controlled trials of bitter melon have been conducted. Study designs 
differed and a meta-analysis pooling results was not performed. A statistically significant mean 
decrease in fructosamine, following a 4-week regimen of 2,000 mg/day of bitter melon, compared with 
baseline levels, was reported in a clinical trial (randomization to 4 groups, intention-to-treat design) of 
patients with newly diagnosed type 2 diabetes conducted at four hospitals in Thailand (−10.2; 95% 
confidence interval=−19.1–1.3 µmol/L) [36]. Roasted rice powder (which has a high glycemic load) 
was used as the placebo comparison. Paradoxically, bitter melon had no apparent effect on fasting 
glucose or 2-hour glucose tolerance measurements. Three other groups were tested in this study and it 
is not clear if the statistical significance of the above finding holds after adjustment for multiplicity.  
In another positive randomized clinical study (n = 15 noninsulin dependent diabetics), bitter melon 
was observed to act in synergy with two oral hypoglycemics (metformin, glibenclamide) [48]. After  
7 days of treatment, greater than full dose efficacy (10% to 21% reduced sugar levels) was seen for 
bitter melon plus half doses of metformin and glibenclamide, illustrating the potentiated effect of the 
combined administration in diabetics. However, residual confounding, given the small sample of the 
study, could have biased the results.  
No statistically significant change in serum fructosamine over time (baseline to 4 weeks of 
treatment) was observed for bitter melon (6,000 mg/day) compared with placebo (riboflavin) in a 
randomized controlled clinical trial (treatment n = 26; Placebo n = 24) [39]. While a mean drop in 
fructosamine from 350.8 to 319.1 mg/dL was observed for the bitter melon arm from baseline to  
4 weeks, an unexplained drop in the placebo group also was observed over the same time period (349.1 
to 333.9 mg/dL). Details were not provided regarding the standardization of bitter melon or whether 
patients complied with their routine oral hypoglycemic agents. Similarly, the mean beneficial change 
in fasting blood sugar levels from pre- to post-treatment (3 months, mean decrease = 0.41 mmol/L) 
with bitter melon was not statistically significant in a randomized, double-blind, placebo-controlled 
trial conducted at outpatient clinics in the Philippines [35]. However, the achieved power for this study 
was only 11%. Another (non-peer reviewed) study, conducted over a 10-year period by the Philippine 
Council for Health Research and Development (PCHRD) reported that a 100-milligram per kilo dose 
per day of bitter melon was clinically comparable to 2.5 mg of the anti-diabetic drug glibenclamide Int. J. Environ. Res. Public Health 2014, 11 2339 
 
taken twice per day [45,53] for regulating blood sugar [45]. A pilot study conducted in five   
non-diabetic overweight men did not observe any effect on plasma glucose levels after they consumed 
a freeze-dried juice extract (100 mg/kg body weight) of bitter melon [14].  
Recently, a prospective, randomized, double-blinded and placebo-controlled trial of bitter melon 
reported a statistically significance decrease in HbA1c levels after 4 mouths of intervention, compared 
with a referent group receiving refined soybean oil [51]. In this study, bitter melon was administered as 
a special water soluble power (2 g daily dose), standardized at 10% charantin. Bitter melon was   
well-tolerated and no apparent differences in liver function values were observed in comparison with 
the referent group. In a study of 40 newly diagnosed patients with type 2 diabetes mellitus (18 males,  
22 females), a single dose (100 mg/kg/day) of bitter melon was observed to be significantly more 
effective than those randomized to placebo (double-blind) in reducing mealtime glycemic excursions 
(within post-dose window) and reverting more rapidly to baseline levels [43]. 
Alone, few side effects have been associated with the use of bitter melon. No deaths have been 
reported to date. The most commonly observed adverse effects include mild diarrhea and abdominal 
pain, which subside after discontinuing use [54]. However, bitter melon has been shown to potentiate 
the effect of certain drugs used to treat diabetes, possibly resulting in hypoglycemia [52]. Rare cases of 
hypoglycemic coma and convulsions have been reported in children drinking bitter melon tea [55].  
A single case report has suggested that bitter melon may induce paroxysmal atrial fibrillation, based on 
a Naranjo adverse drug reaction score of 6 (corresponding to a probable causal association) [56]. Bitter 
melon use also is contraindicated during pregnancy because of its abortifacient properties [57]. The 
risk associated with the long-term use of bitter melon has not been studied. 
4. Synthesis of the Literature 
Differences in the effectiveness observed across studies examining the potential glucose lowering 
effects of bitter melon may be attributable to several factors. Ayurvedic physicians typically insist on 
the daily preparation of herbal diabetic remedies intended for oral consumption [50]. The aqueous 
extract of Aegle Marmelos, a herb reputed to have oral hypoglycemic activity similar to bitter melon, 
reportedly loses 66% of its maximum hypoglycemic potency after just 72 h of room temperature 
storage [50]. The decline in potency is believed to be due to either bacterial activity or other yet-to-be 
understood explanations [50]. Factors potentially influencing bitter melon efficacy include differences 
in soil/climate, harvest time, part of the plant used (e.g., leaves are believed to be more effective), and 
how the plant is cooked and prepared (e.g., over-heating, the addition of other ingredients that may 
affect absorption). Different variants of bitter melon (shape, color, size) also may be found throughout 
the world and could affect the biologic activity of the herb [58]. Information on the above factors 
typically was not collected in the studies considered for this review. Furthermore, studies often lacked 
a population-based referent group, were not adequately blinded, failed to conceal allocation assignment, 
were too short in duration to yield effect, or suffered from selection bias (not randomized) [36]. Such 
biases tend to be associated with inflated study benefits [59,60]. In other cases, statistical methodology, 
design details, and study conduct (e.g., inclusion/exclusion criteria, ethnic background of patients, 
drop-out rates, a priori power analysis, baseline comparability, outcome measures, and treatment 
adherence/integrity) were not adequately described to allow a definitive comparison across studies or a Int. J. Environ. Res. Public Health 2014, 11 2340 
 
basic assessment of face validity [61,62]. Among the manuscripts reviewed in Table 2, less than 20% 
received a quality score of two or greater on the Jadad scale [62]. 
While bitter melon holds promise for the safe and affordable prevention and control of high blood 
sugar among pre-diabetics, primary care providers must err on the side of caution and appropriately 
advise patients not to forego medical consultation and conventional therapy (especially as their disease 
progresses) in lieu of anecdotal evidence or recommendation from traditional herbal practitioners. 
Patients with poor glycemic control, cardiovascular disease, fatty liver disease, and polycystic ovary 
syndrome must be closely monitored and queried regarding their use of bitter melon and other herbal 
products that may interact with conventional medicines such as metformin and acarbose [63,64]. 
Furthermore, drugs approved by the Food and Drug Administration (FDA) that increase insulin 
sensitivity (e.g., pioglitazone) may help reduce the risk of converting from pre-diabetes to diabetes, 
without the uncertainty in dosing and potential for interaction associated with the uncontrolled use of 
bitter melon. Bariatric surgery also remains a proven intervention to control the progression to diabetes [2]. 
Nevertheless, the use of bitter melon may be warranted in certain individuals, such as patients 
without health insurance, those living in rural areas far from health care, members of ethnic/religious 
groups who do not subscribe to conventional medical care or surgery, and non-compliant patients (e.g., 
those with difficulty swallowing pills). An increasing prevalence of pre-diabetics has been noted in 
remote, rural regions, especially those with a high number of elderly residents [65]. Further assessment 
of the benefits and risks of bitter melon use in these groups is recommended. 
Reducing healthcare costs also may be a factor prompting the use of bitter melon and other 
alternative therapies aimed at preventing and controlling high blood sugar. An advantage of medicinal 
plants such as bitter melon is that they may be inexpensively cultivated in gardens and greenhouses. 
However, potential short-term savings must be weighed in light of the effectiveness of bitter melon (or 
lack thereof) and the proclivity of patients to delay using clinically proven therapies. Additionally, the 
acceptance of bitter melon may be limited due to its undesirable bitter taste [66]. Research needs to be 
directed toward strategies for improving the palatability and consumption intentions of food dishes 
containing bitter melon. 
5. Conclusions 
Overall, it remains controversial whether bitter melon has proven benefits in lowering blood sugar 
among pre-diabetics or aids in slowing the progression to diabetes. While the evidence to date, when 
examined as a whole, is suggestive of a possible beneficial effect, future clinical studies that meet 
rigorous methodological standards are warranted before attempts to establish policy recommendations 
regarding the use of this herb among pre-diabetics.  
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